Long-term safety and efficacy of the novel β3-adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study-Reference-Cited by-同舟云学术

Long-term safety and efficacy of the novel β3-adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study

Published:2018-05-11 Issue:7 Volume:25 Page:668-675
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int. J. Urol.

Author:

Yoshida Masaki¹,Kakizaki Hidehiro²,Takahashi Satoru³,Nagai Shinji⁴,Kurose Takafumi⁴

Affiliation:

1. Department of Urology; National Centre for Geriatrics and Gerontology; Obu Aichi

2. Department of Renal and Urologic Surgery; Asahikawa Medical University; Asahikawa Hokkaido Japan

3. Department of Urology; Nihon University School of Medicine, Tokyo; Tokyo Japan

4. Kyorin Pharmaceutical; Tokyo Japan

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/iju.13596/fullpdf

Reference24 articles.

1. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society;Abrams;Neurourol. Urodyn.,2002

2. An epidemiological survey of overactive bladder symptoms in Japan;Homma;BJU Int.,2005

3. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study;Irwin;Eur. Urol.,2006

4. Prevalence and burden of overactive bladder in the United States;Stewart;World J. Urol.,2003

5. Impact of urinary incontinence and overactive bladder on quality of life;Chiaffarino;Eur. Urol.,2003

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of a new selective β₃‐adrenoceptor agonist, vibegron, on bladder and urethral function in a rat model of Parkinson's disease;LUTS: Lower Urinary Tract Symptoms;2023-09-18

2. Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density;PLOS ONE;2023-09-01

3. A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder;International Neurourology Journal;2023-06-30

4. Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study;Urology;2023-05

5. Eczematous eruption associated with two beta‐3 adrenergic agonists for overactive bladder;International Journal of Dermatology;2023-04-17